Treatment Satisfaction and Decision‐making from the Patient Perspective in Axial Spondyloarthritis: Real‐World Data from a Descriptive Cross‐sectional Survey Study from the ArthritisPower Registry
Autor: | William N Malatestinic, W. B. Nowell, Jeffrey R. Curtis, Carol Himelein, Rebecca Bolce, Jessica A. Walsh, Jeffrey R. Lisse, Theresa Hunter, K. Gavigan |
---|---|
Rok vydání: | 2021 |
Předmět: |
education.field_of_study
medicine.medical_specialty Cross-sectional study business.industry Perspective (graphical) Population MEDLINE Diseases of the musculoskeletal system Disease Treatment satisfaction RC925-935 Rheumatology Joint pain Family medicine Medicine Original Article medicine.symptom Axial spondyloarthritis education business |
Zdroj: | ACR Open Rheumatology ACR Open Rheumatology, Vol 4, Iss 1, Pp 85-94 (2022) |
ISSN: | 2578-5745 |
DOI: | 10.1002/acr2.11365 |
Popis: | Objective Aims were to 1) to characterize patient decision-making with treatment for axial spondyloarthritis (axSpA) and 2) to explore relationships among decision-making, treatment satisfaction, and biologic disease modifying antirheumatic drugs (bDMARDs). Methods ArthritisPower participants with physician-diagnosed axSpA were invited to complete an online survey about their treatment and their most recent physician visit. Analysis compared treatment decision by satisfaction and bDMARD status. Results Among the 274 participants, 87.2% were female, and the mean age was 50 years. Of participants, 79.5% had researched treatment before their most recent physician visit, and 56.9% discussed treatment change at their most recent physician visit. Of treatment-change discussions, 69.2% of them were related to escalation, compared with deescalation (27.6%) and/or switching (39.1%). Among those participants who discussed a change, 73.7% agreed to it because they felt that their disease was not being controlled (54.9%) or felt that it could be better controlled on new treatment (20.3%). Top symptoms prompting change were back/buttock pain (63.3%), other joint pain (55.1%), and fatigue (54.1%). Among bDMARD-treated participants (n = 128), important factors for treatment decisions were prevention of long-term axSpA consequences (92.9%) and doctor's advice (87.5%). Among 43.4% of participants reporting treatment dissatisfaction, 37% did not discuss treatment change. Current bDMARD use was more common in satisfied (61.9%) than dissatisfied participants (26.9%). Conclusion In this cross-sectional study of a predominantly female axSpA population, patients frequently researched treatment options and discussed escalation with their providers. Under two-thirds of participants who were dissatisfied with treatment discussed changes at their most recent visit. Current bDMARD use was associated with higher satisfaction, and bDMARD users considered prevention of long-term consequences and doctor's advice to be very important for decision-making. |
Databáze: | OpenAIRE |
Externí odkaz: |